Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARK L WARREN

Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism

NPI
1629073010
CMS profile
209984
Location
GREENVILLE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$115,723.95

199 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Novo Nordisk Inc $62,720.36 80
Lilly USA, LLC $18,241.16 22
Amgen Inc. $12,340.41 28
Abbott Laboratories $9,868.26 26
Eli Lilly and Company $7,351.64 20
Mannkind Corporation $3,605.88 4
Esperion Therapeutics, Inc. $760.00 1
SANOFI-AVENTIS U.S. LLC $160.34 8
Medtronic, Inc. $155.64 1
Horizon Therapeutics plc $155.52 5
Nevro Corp. $147.50 1
Bayer HealthCare Pharmaceuticals Inc. $124.99 1
Insulet Corporation $74.51 1
Baxter Healthcare $17.74 1

Page 3 of 4; records 101–150 of 199 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARK L WARREN

NPI 1629073010 · CMS profile ID 209984

Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism

GREENVILLE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 199 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1629073010?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARK L WARREN, NPI 1629073010, CMS profile ID 209984. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 199 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1629073010?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). MARK L WARREN, NPI 1629073010, CMS profile ID 209984. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 199 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1629073010?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
MARK L WARREN, NPI 1629073010, CMS profile ID 209984, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 199 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1629073010?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

199 matching records · $115,723.95 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 199 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 199.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $2,400.0006/07/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939339499 CMS
Amgen Inc. $39.7806/07/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939339511 CMS
Amgen Inc. $2,400.0006/07/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939339513 CMS
Amgen Inc. $400.0006/07/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939339515 CMS
Amgen Inc. $1.6206/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939339521 CMS
Lilly USA, LLC $1,100.0006/03/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918181879 CMS
Novo Nordisk Inc $131.0406/03/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898882015 CMS
Novo Nordisk Inc $3,485.0006/03/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898892451 CMS
Novo Nordisk Inc $49.7106/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899304101 CMS
Novo Nordisk Inc $26.3306/02/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898881983 CMS
Novo Nordisk Inc $16.6106/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899304085 CMS
Novo Nordisk Inc $2,210.0006/02/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899304149 CMS
Novo Nordisk Inc $12.0105/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899312287 CMS
Amgen Inc. $2,400.0005/24/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939339505 CMS
Amgen Inc. $400.0005/24/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939339507 CMS
Amgen Inc. $882.0005/23/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939339503 CMS
Mannkind Corporation $2,975.0005/21/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942768585 CMS
Abbott Laboratories $900.0005/19/2022 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920511577 CMS
Amgen Inc. $71.7105/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939339501 CMS
Amgen Inc. $11.4505/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939339531 CMS
SANOFI-AVENTIS U.S. LLC $5.2005/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938794877 CMS
Abbott Laboratories $3.3005/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920525883 CMS
Mannkind Corporation $619.6405/09/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942768583 CMS
Novo Nordisk Inc $42.1205/09/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898542735 CMS
Novo Nordisk Inc $2,635.0005/09/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898730963 CMS
Novo Nordisk Inc $13.1905/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898830703 CMS
Abbott Laboratories $25.0005/06/2022 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 910338571 CMS
Abbott Laboratories $875.0005/05/2022 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920511569 CMS
Amgen Inc. $107.7405/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939339517 CMS
Amgen Inc. $3.2405/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939339519 CMS
Novo Nordisk Inc $11.7705/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898530921 CMS
Novo Nordisk Inc $65.5205/04/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898542739 CMS
Novo Nordisk Inc $2,975.0005/04/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898567983 CMS
Abbott Laboratories $0.7405/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920542083 CMS
Abbott Laboratories $108.9505/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920542093 CMS
Novo Nordisk Inc $1,700.0005/02/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898569265 CMS
Abbott Laboratories $85.3904/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920511563 CMS
Lilly USA, LLC $1,100.0004/28/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918212079 CMS
Abbott Laboratories $19.0504/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914241613 CMS
Lilly USA, LLC $1,100.0004/27/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918190269 CMS
Novo Nordisk Inc $6.9204/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898740917 CMS
SANOFI-AVENTIS U.S. LLC $100.0004/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938794875 CMS
Amgen Inc. $124.9904/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939339495 CMS
Novo Nordisk Inc $107.6404/21/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898542745 CMS
Novo Nordisk Inc $163.8904/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898569342 CMS
Novo Nordisk Inc $512.1904/21/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898882037 CMS
Novo Nordisk Inc $3,655.0004/21/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898892459 CMS
Novo Nordisk Inc $258.4904/21/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899304109 CMS
Novo Nordisk Inc $744.1504/21/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899304133 CMS
Lilly USA, LLC $50.0204/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918190271 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $259,060.54 474
PY2020 $130,717.50 279
PY2021 $131,517.76 207
PY2022 $115,723.95 199
PY2023 $84,478.07 156
PY2024 $65,629.93 188
PY2025 $128,259.42 199

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $500,365.48 199
PY2024 Recipient $17,123.42 29
PY2024 Principal investigator $769,344.58 122
PY2023 Recipient $1,173.86 8
PY2023 Principal investigator $453,635.21 173
PY2022 Recipient $1,754.86 8
PY2022 Principal investigator $568,061.57 200
PY2021 Principal investigator $588,948.55 2,089
PY2020 Recipient $1,190.00 3
PY2020 Principal investigator $493,531.93 476
PY2019 Recipient $1,642.00 1
PY2019 Principal investigator $750,222.66 183

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

199 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $5,520.00 12/31/2025 Non-covered Recipient Entity
PHYSICIANS EAST PA
A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism No dispute reported 06/30/2026 1202534039
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 12/17/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653446
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,473.10 12/10/2025 Non-covered Recipient Entity
Physicians East PA MRI
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220791302
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6,000.00 12/03/2025 Non-covered Recipient Entity
Physicians East PA - 1006 WH Smith
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215508340
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,598.00 12/03/2025 Non-covered Recipient Entity
Physicians East PA - 1006 WH Smith
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215508345
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653310
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653312
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653444
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220653458
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 11/20/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220995392
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 11/19/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653314
Principal investigator 1 Boehringer Ingelheim International GmbH $292.00 11/19/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653316
Principal investigator 1 Boehringer Ingelheim International GmbH $13.92 11/19/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653318
Principal investigator 1 Boehringer Ingelheim International GmbH $16.56 11/19/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653320
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,816.10 11/13/2025 Non-covered Recipient Entity
Physicians East PA MRI
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220791300
Principal investigator 1 ABBVIE INC. $16,861.00 11/05/2025 Non-covered Recipient Entity
PHYSICIANS EAST PA
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202521697
Principal investigator 1 Ascendis Pharma Endocrinology Inc $463.00 11/03/2025 Non-covered Recipient Entity
Physicians East, PA
EAP of Palopegteriparatide in Patients With Hypoparathyroidism No dispute reported 06/30/2026 1233997446
Principal investigator 1 Ascendis Pharma Endocrinology Inc $463.00 11/03/2025 Non-covered Recipient Entity
Physicians East, PA
EAP of Palopegteriparatide in Patients With Hypoparathyroidism No dispute reported 06/30/2026 1233997448
Principal investigator 1 Ascendis Pharma Endocrinology Inc $463.00 11/03/2025 Non-covered Recipient Entity
Physicians East, PA
EAP of Palopegteriparatide in Patients With Hypoparathyroidism No dispute reported 06/30/2026 1233997450
Principal investigator 1 Ascendis Pharma Endocrinology Inc $463.00 11/03/2025 Non-covered Recipient Entity
Physicians East, PA
EAP of Palopegteriparatide in Patients With Hypoparathyroidism No dispute reported 06/30/2026 1233997452
Principal investigator 1 Ascendis Pharma Endocrinology Inc $369.00 11/03/2025 Non-covered Recipient Entity
Physicians East, PA
EAP of Palopegteriparatide in Patients With Hypoparathyroidism No dispute reported 06/30/2026 1233997468
Principal investigator 1 Ascendis Pharma Endocrinology Inc $369.00 11/03/2025 Non-covered Recipient Entity
Physicians East, PA
EAP of Palopegteriparatide in Patients With Hypoparathyroidism No dispute reported 06/30/2026 1233997470
Principal investigator 1 Ascendis Pharma Endocrinology Inc $369.00 11/03/2025 Non-covered Recipient Entity
Physicians East, PA
EAP of Palopegteriparatide in Patients With Hypoparathyroidism No dispute reported 06/30/2026 1233997472
Principal investigator 1 Ascendis Pharma Endocrinology Inc $369.00 11/03/2025 Non-covered Recipient Entity
Physicians East, PA
EAP of Palopegteriparatide in Patients With Hypoparathyroidism No dispute reported 06/30/2026 1233997474
Principal investigator 1 Ascendis Pharma Endocrinology Inc $263.00 11/03/2025 Non-covered Recipient Entity
Physicians East, PA
EAP of Palopegteriparatide in Patients With Hypoparathyroidism No dispute reported 06/30/2026 1233997476
Principal investigator 1 Ascendis Pharma Endocrinology Inc $263.00 11/03/2025 Non-covered Recipient Entity
Physicians East, PA
EAP of Palopegteriparatide in Patients With Hypoparathyroidism No dispute reported 06/30/2026 1233997478
Principal investigator 1 Ascendis Pharma Endocrinology Inc $263.00 11/03/2025 Non-covered Recipient Entity
Physicians East, PA
EAP of Palopegteriparatide in Patients With Hypoparathyroidism No dispute reported 06/30/2026 1233997480
Principal investigator 1 Ascendis Pharma Endocrinology Inc $263.00 11/03/2025 Non-covered Recipient Entity
Physicians East, PA
EAP of Palopegteriparatide in Patients With Hypoparathyroidism No dispute reported 06/30/2026 1233997482
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653308
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653440
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653442
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220653456
Principal investigator 1 Novo Nordisk AS $1,064.25 10/29/2025 Non-covered Recipient Entity
PHYSICIANS EAST ENDOCRINOLOGY
NN8640-4515 No dispute reported 06/30/2026 1213706610
Principal investigator 1 Boehringer Ingelheim International GmbH $259.74 10/27/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220653460
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 10/27/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220653462
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $4,933.00 10/16/2025 Non-covered Recipient Entity
Physicians East Pa
A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a No dispute reported 06/30/2026 1225413942
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $9,376.20 10/10/2025 Non-covered Recipient Entity
Physicians East PA MRI
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220791284
Principal investigator 1 ABBVIE INC. $13,505.70 10/09/2025 Non-covered Recipient Entity
PHYSICIANS EAST PA
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202514977
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653306
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653434
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653436
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653438
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 10/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220653448
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 10/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220653450
Principal investigator 1 Boehringer Ingelheim International GmbH $23.75 10/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220653452
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220653454
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 09/24/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653304
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 09/24/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653432
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 09/17/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220794429
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 09/17/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220794431
Principal investigator 1 ABBVIE INC. $9,629.10 09/04/2025 Non-covered Recipient Entity
PHYSICIANS EAST PA
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202508702
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,890.00 09/03/2025 Non-covered Recipient Entity
Physicians East PA MRI
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220791286
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653280
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653282
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653284
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653286
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653396
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653398
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653400
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653402
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653420
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653422
Principal investigator 1 Novo Nordisk AS $1,064.25 08/22/2025 Non-covered Recipient Entity
PHYSICIANS EAST ENDOCRINOLOGY
NN8640-4515 No dispute reported 06/30/2026 1213727181
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,061.90 08/20/2025 Non-covered Recipient Entity
Physicians East PA MRI
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220791298
Principal investigator 1 ABBVIE INC. $14,677.00 08/06/2025 Non-covered Recipient Entity
PHYSICIANS EAST PA
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202502512
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653272
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653274
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653276
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653278
Principal investigator 1 Boehringer Ingelheim International GmbH $61.58 08/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653412
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653418
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $13,977.00 08/01/2025 Non-covered Recipient Entity
Physicians East PA MRI
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220791282
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,251.00 07/31/2025 Non-covered Recipient Entity
Physicians East Pa
A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a No dispute reported 06/30/2026 1225413356
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 07/28/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653296
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 07/28/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653298
Principal investigator 1 Boehringer Ingelheim International GmbH $3.48 07/28/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653300
Principal investigator 1 Boehringer Ingelheim International GmbH $4.14 07/28/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653302
Principal investigator 1 Boehringer Ingelheim International GmbH $79.92 07/28/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653424
Principal investigator 1 Boehringer Ingelheim International GmbH $584.00 07/28/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653426
Principal investigator 1 Boehringer Ingelheim International GmbH $27.84 07/28/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653428
Principal investigator 1 Boehringer Ingelheim International GmbH $33.12 07/28/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653430
Principal investigator 1 Eli Lilly and Company $1,072.00 07/28/2025 Non-covered Recipient Entity
DANBURY CLINICAL RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187878639
Principal investigator 1 Ascendis Pharma Endocrinology Inc $2,608.20 07/10/2025 Non-covered Recipient Entity
KMW, Inc
PaTHway TRIAL No dispute reported 06/30/2026 1233996533
Principal investigator 1 Ascendis Pharma Endocrinology Inc $1,950.00 07/10/2025 Non-covered Recipient Entity
KMW, Inc
PaTHway TRIAL No dispute reported 06/30/2026 1233996535
Principal investigator 1 Ascendis Pharma Endocrinology Inc $1,090.80 07/10/2025 Non-covered Recipient Entity
KMW, Inc
PaTHway TRIAL No dispute reported 06/30/2026 1233996537
Principal investigator 1 Ascendis Pharma Endocrinology Inc $1,060.80 07/10/2025 Non-covered Recipient Entity
KMW, Inc
PaTHway TRIAL No dispute reported 06/30/2026 1233996539
Principal investigator 1 Ascendis Pharma Endocrinology Inc $1,060.80 07/10/2025 Non-covered Recipient Entity
KMW, Inc
PaTHway TRIAL No dispute reported 06/30/2026 1233996541
Principal investigator 1 Ascendis Pharma Endocrinology Inc $892.00 07/10/2025 Non-covered Recipient Entity
KMW, Inc
PaTHway TRIAL No dispute reported 06/30/2026 1233996543
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $900.00 07/09/2025 Non-covered Recipient Entity
Physicians East PA MRI
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220791296
Principal investigator 1 ABBVIE INC. $23,284.30 07/02/2025 Non-covered Recipient Entity
PHYSICIANS EAST PA
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202494121
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653288
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653290
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653292
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653294
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653404
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653406
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653408
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653410
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653414
Principal investigator 1 Boehringer Ingelheim International GmbH $43.00 07/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653416
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 06/24/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653268
Principal investigator 1 Boehringer Ingelheim International GmbH $1.74 06/24/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653270
Principal investigator 1 Boehringer Ingelheim International GmbH $23.32 06/24/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653390
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 06/24/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653392
Principal investigator 1 Boehringer Ingelheim International GmbH $1.74 06/24/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653394
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,805.80 06/12/2025 Non-covered Recipient Entity
Physicians East PA MRI
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220791280
Principal investigator 1 ABBVIE INC. $35,578.40 06/03/2025 Non-covered Recipient Entity
PHYSICIANS EAST PA
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202488529
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653254
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653256
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653258
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653260
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653376
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653378
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653380
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653382
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653384
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $60.00 05/12/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220794425
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $60.00 05/12/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220794427
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,061.90 05/09/2025 Non-covered Recipient Entity
Physicians East PA MRI
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220791294
Principal investigator 1 ABBVIE INC. $14,794.00 05/07/2025 Non-covered Recipient Entity
PHYSICIANS EAST PA
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202482595
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $19.89 05/06/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220794423
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,622.40 05/05/2025 Non-covered Recipient Entity
Physicians East PA MRI
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220791278
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653246
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653248
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653250
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653252
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 05/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653366
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653368
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653370
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653372
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653374
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,890.80 05/01/2025 Non-covered Recipient Entity
Physicians East PA MRI
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220791276
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $900.00 05/01/2025 Non-covered Recipient Entity
Physicians East PA MRI
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220791292
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,619.00 04/28/2025 Non-covered Recipient Entity
Physicians East Pa
BAY 948862, A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney No dispute reported 06/30/2026 1225403693
Principal investigator 1 Amgen Inc. $22,133.00 04/24/2025 Non-covered Recipient Entity
PHYSICIANS EAST PA
A Study to Evaluate the Efficacy, Safety & Tolerability of Maridebart Cafraglutide in Adults With T2DM No dispute reported 06/30/2026 1246646528
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 04/23/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653262
Principal investigator 1 Boehringer Ingelheim International GmbH $6.96 04/23/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653264
Principal investigator 1 Boehringer Ingelheim International GmbH $8.28 04/23/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653266
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 04/23/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653386
Principal investigator 1 Boehringer Ingelheim International GmbH $3.48 04/23/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653388
Principal investigator 1 ABBVIE INC. $4,890.60 04/03/2025 Non-covered Recipient Entity
PHYSICIANS EAST PA
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202471525
Principal investigator 1 Ascendis Pharma Endocrinology Inc $2,678.40 04/03/2025 Non-covered Recipient Entity
KMW, Inc
PaTHway TRIAL No dispute reported 06/30/2026 1233995285
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653238
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653240
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653242
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653244
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653356
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653358
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653360
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653362
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 04/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653364
Principal investigator 1 Novo Nordisk AS $22,865.48 03/31/2025 Non-covered Recipient Entity
PHYSICIANS EAST, PA
EX9924-4473 No dispute reported 06/30/2026 1213774291
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,227.00 03/27/2025 Non-covered Recipient Entity
Physicians East Pa
BAY 948862, A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney No dispute reported 06/30/2026 1225404684
Principal investigator 1 Ascendis Pharma Endocrinology Inc $15,902.88 03/26/2025 Non-covered Recipient Entity
KMW, Inc
PaTHway TRIAL No dispute reported 06/30/2026 1233995239
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,099.70 03/24/2025 Non-covered Recipient Entity
Physicians East PA MRI
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220791290
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,318.70 03/13/2025 Non-covered Recipient Entity
Physicians East PA MRI
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220791274
Principal investigator 1 Eli Lilly and Company $10,217.00 03/11/2025 Non-covered Recipient Entity
PHYSICIANS EAST
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187889498
Principal investigator 1 ABBVIE INC. $17,685.20 03/07/2025 Non-covered Recipient Entity
PHYSICIANS EAST PA
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202459473
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,579.00 03/06/2025 Non-covered Recipient Entity
Physicians East Pa
BAY 948862, A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney No dispute reported 06/30/2026 1225403239
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653230
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653232
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653234
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653236
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653340
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653342
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653344
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653346
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 03/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653348
Principal investigator 1 Amgen Inc. $7,370.41 02/25/2025 Non-covered Recipient Entity
PHYSICIANS EAST
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2) No dispute reported 06/30/2026 1246646532
Principal investigator 1 AstraZeneca Pharmaceuticals LP $25,801.75 02/21/2025 Non-covered Recipient Entity
PHYSICIANS EAST URGENT CARE CENTER
A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of Zibotentan/Dapagliflozin FDC Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease and High Proteinuria No dispute reported 06/30/2026 1185538176
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,647.40 02/21/2025 Non-covered Recipient Entity
Physicians East PA MRI
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220791272
Principal investigator 1 ABBVIE INC. $7,373.60 02/06/2025 Non-covered Recipient Entity
PHYSICIANS EAST PA
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202446883
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653222
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653224
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653226
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653228
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653330
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653332
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653334
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653336
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 02/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653338
Principal investigator 1 Amgen Inc. $42,888.34 01/30/2025 Non-covered Recipient Entity
PHYSICIANS EAST
A Study to Evaluate the Efficacy, Safety & Tolerability of Maridebart Cafraglutide in Adults With T2DM No dispute reported 06/30/2026 1246646536
Principal investigator 1 Medtronic, Inc. $59.00 01/30/2025 Non-covered Recipient Entity
Kmw Inc
CIP341 IMPACT2 No dispute reported 06/30/2026 1192322783
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $7,209.00 01/28/2025 Non-covered Recipient Entity
Physicians East Pa
BAY 948862, A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney No dispute reported 06/30/2026 1225403085
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 01/27/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653350
Principal investigator 1 Boehringer Ingelheim International GmbH $5.22 01/27/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653352
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,329.00 01/22/2025 Non-covered Recipient Entity
Physicians East PA MRI
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220791270
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $900.00 01/17/2025 Non-covered Recipient Entity
Physicians East PA MRI
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220791288
Principal investigator 1 Alexion Pharmaceuticals, Inc. $39,699.37 01/16/2025 Non-covered Recipient Entity
KMW INCORPORATED
Eneboparatide - Calypso study which is a pivotal phase 3 study investigational therapeutic peptide with a novel mechanism of action for hypoparathyroidism No dispute reported 06/30/2026 1185538178
Principal investigator 1 AstraZeneca Pharmaceuticals LP $15,665.87 01/08/2025 Non-covered Recipient Entity
PHYSICIANS EAST URGENT CARE CENTER
a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure No dispute reported 06/30/2026 1185538174
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653214
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653216
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653218
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220653220
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653322
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653324
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653326
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653328
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 01/01/2025 Non-covered Recipient Entity
Physicians East Properties LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220653354